Public Employees Retirement Association of Colorado’s Revolution Medicines RVMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.51M Hold
13,423
0.01% 498
2026
Q1
$1.3M Hold
13,423
0.01% 610
2025
Q4
$1.07M Hold
13,423
﹤0.01% 673
2025
Q3
$627K Hold
13,423
﹤0.01% 863
2025
Q2
$494K Hold
13,423
﹤0.01% 972
2025
Q1
$475K Hold
13,423
﹤0.01% 961
2024
Q4
$587K Hold
13,423
﹤0.01% 897
2024
Q3
$609K Hold
13,423
﹤0.01% 887
2024
Q2
$521K Sell
13,423
-263
-2% -$9.83K ﹤0.01% 937
2024
Q1
$441K Hold
13,686
﹤0.01% 1048
2023
Q4
$393K Sell
13,686
-1,353
-9% -$32.5K ﹤0.01% 1164
2023
Q3
$416K Hold
15,039
﹤0.01% 1064
2023
Q2
$402K Hold
15,039
﹤0.01% 1172
2023
Q1
$326K Sell
15,039
-14,097
-48% -$347K ﹤0.01% 1303
2022
Q4
$694K Buy
+29,136
New +$620K ﹤0.01% 862

Other funds holding RVMD

Public Employees Retirement Association of Colorado's RVMD Position: Q2 2026 in Review

Public Employees Retirement Association of Colorado held its Revolution Medicines (RVMD) position steady in Q2 2026 at 13,423 shares worth $2.51M. The position accounts for 0.01% of the portfolio, ranked #498.

Public Employees Retirement Association of Colorado first reported a position in RVMD in Q4 2022 and has held it in 15 quarters since. 690 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • Public Employees Retirement Association of Colorado held 13,423 shares of Revolution Medicines worth $2.51M as of Q2 2026.
  • Public Employees Retirement Association of Colorado left its Revolution Medicines share count unchanged in Q2 2026.
  • Revolution Medicines made up 0.01% of Public Employees Retirement Association of Colorado's portfolio in Q2 2026, its #498 holding.
  • Public Employees Retirement Association of Colorado first reported a position in Revolution Medicines in Q4 2022 and has held it in 15 quarters since.
  • 690 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Public Employees Retirement Association of Colorado's 13F filing for Q2 2026, filed 11 Aug 2026.